By Fineline Cube 
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced an exclusive licensing agreement with Apotex Inc., granting the US firm exclusive commercialization rights to its clobetasol propionate ophthalmic suspension, 0.05% (APP13007) in Mexico. The deal builds on a previous transaction between the two companies regarding the rights to the drug in Canada. No financial details were disclosed.
APP13007 Overview
APP13007’s active ingredient is the superpotent corticosteroid, clobetasol propionate, derived from Formosa Pharma’s proprietary APNT nanoparticle formulation platform. The drug was approved by the US Food and Drug Administration (FDA) in 2024 for the treatment of inflammation and pain following ocular surgery.
Global Partnerships
Formosa Pharma has established partnerships with Grand Pharma, Cristália Produtos Quimicos Farmaceuticos Ltda, Tabuk Pharma, Apotex, and Cipla for the drug’s commercialization in Chinese Mainland, Hong Kong, Macao, Brazil, the Middle East, North Africa, and Southeast Asia. The latest agreement with Apotex further expands the drug’s market reach in Latin America.-Fineline Info & Tech